Marker Therapeutics (MRKR)
NASDAQ:MRKR
Want to see MRKR full AI Analyst Report?
MRKR Stock Chart & Stats
$1.66
-$0.17(-5.70%)
At close: 4:00 PM EST
$1.66
-$0.17(-5.70%)
Day’s Range― - ―
52-Week Range$0.81 - $4.07
Previous CloseN/A
Volume39.59K
Average Volume (3M)66.19K
Market Cap
$23.84M
Enterprise Value$2.04M
Total Cash (Recent Filing)$14.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,673,126
10 Day Avg. Volume70,915
30 Day Avg. Volume66,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit-0.98
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$9.00Price Target Upside442.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$2.73M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-free balance sheet reduces interest burden and financial distress risk, providing durable optionality to fund trials or restructure financing. With no reported debt across recent years, the company retains strategic flexibility when raising capital or pursuing partnerships over the next 2–6 months.
Platform & PipelineMarker’s multi-antigen adoptive T‑cell platform targets tumor-escape and applies to hematologic and solid tumors. This structural scientific approach can deliver lasting competitive differentiation if clinical efficacy emerges, supporting durable value creation through platform leverage across indications.
Financing Flexibility Via Share AuthorizationBoard-approved expansion of authorized shares materially increases capacity to raise equity or structure strategic deals, a lasting corporate governance tool that supports funding for clinical programs and operations, reducing immediate insolvency risk while enabling multi-quarter development plans.
Bears Say
Negative Gross Profit & Ongoing LossesPersistent negative gross profit and sizable operating losses indicate the core business is not yet economically viable. Over the medium term, this undermines margin sustainability and requires sustained external funding until clinical programs translate into revenue-generating products or scalable services.
Persistent Cash BurnConsistent negative operating and free cash flow shows the company cannot self-fund R&D or operations. This structural cash burn increases dependency on capital markets, heightens dilution risk, and constrains long-term planning unless clinical progress materially improves funding prospects.
Small, Declining Revenue BaseA small, falling revenue base signals weak near-term commercial traction and limits internal resource reinvestment. Without clear trend reversal, scaling operations or funding late-stage trials becomes harder, pressuring margins and making outcomes highly dependent on successful external financing or partnerships.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics’s price range in the past 12 months?
Marker Therapeutics lowest stock price was $0.81 and its highest was $4.07 in the past 12 months.
What is Marker Therapeutics’s market cap?
Marker Therapeutics’s market cap is $23.84M.
When is Marker Therapeutics’s upcoming earnings report date?
Marker Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 154 days.
How were Marker Therapeutics’s earnings last quarter?
Marker Therapeutics released its earnings results on May 20, 2026. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is Marker Therapeutics overvalued?
According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued.
Does Marker Therapeutics pay dividends?
Marker Therapeutics does not currently pay dividends.
What is Marker Therapeutics’s EPS estimate?
Marker Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marker Therapeutics have?
Marker Therapeutics has 16,673,126 shares outstanding.
What happened to Marker Therapeutics’s price movement after its last earnings report?
Marker Therapeutics reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went up 1.439%.
Which hedge fund is a major shareholder of Marker Therapeutics?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(442.17% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
18.09%
Insiders
3.00% Mutual Funds
15.29% Other Institutional Investors
61.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---